Why Is Personalized Dose Adjustment Important for Weight-Loss Injections?
In this article
Pens were designed around clinical trial protocols, rather than the individual
Dose-escalation schedules for drugs such as semaglutide and tirzepatide are based on the strict protocols of “landmark” clinical trials designed to statistically demonstrate efficacy and safety: the dose is generally increased every 4 weeks until the maximum dose is reached. This fixed schedule can cause clinically meaningful gastrointestinal side effects (such as nausea and vomiting), sometimes leading to complete treatment discontinuation.
Eldor et al., Diabetes Care 2025 — a small, open-label, randomized pilot study
- Population: Patients with type 2 diabetes (not yet generalizable to the general population without obesity).
- Comparison: 16-week flexible titration (weekly semaglutide increases of 0,0675 mg) vs the label-recommended 8-week standard titration.
- Result: The number of days with nausea was halved, treatment discontinuation decreased (all-cause discontinuation: 2% vs 19%), and efficacy remained similar.
- Important limitation: A small, open-label pilot study; whether the same result applies to people with obesity (without diabetes) has not yet been demonstrated—an ongoing study is addressing this question (ClinicalTrials.gov: NCT07574723).
Pampanelli et al. (FLEX-SEMA 2.4 mg), Diabetes Obes Metab 2026 — real-world data from Italy
This small retrospective study reported that flexible semaglutide dosing in patients with obesity reduced early treatment discontinuation, while outcomes remained similar to standard dosing. Because of its retrospective design, this finding should also be regarded as supportive, rather than as randomized evidence.
- United States: Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are marketed in single-dose autoinjector pens that do not allow any dose adjustment.
- Canada, the United Kingdom, most EU and Middle Eastern countries: The same drugs are available in multidose pens (FlexTouch, KwikPen), also used in insulin treatment, or in vial form—Türkiye also belongs to this second group.
- February 2026: The FDA approved a 4-dose KwikPen for Zepbound (tirzepatide), used for chronic weight management. (The source article dates this approval to “January 2026”; press reports give the approval date as 23-24 February 2026—we recommend consulting the official FDA announcement for the exact FDA approval date.)
Even multidose pens are insufficient
Even multidose pens mark only standard, large dose steps—there is no continuous/fine-scale indicator for intermediate doses. This deficiency pushes patients toward two risky methods:
- “Click-counting”: Patients try to calculate intermediate doses themselves by counting the pen’s audible/tactile clicks. This method is error-prone because the “amount of drug per click” can differ between pens.
- Withdrawing medication with an insulin syringe: In this even more concerning practice, patients withdraw medication from filled pens using an insulin syringe and create their own doses to save money or use medication remaining in the pen. This carries a risk of dosing errors and contamination.
According to the source article, these behaviors are widely discussed, especially in online patient communities.5
Important safety warning
This article was written to explain the risks of practices such as “click-counting” or withdrawing medication from a pen with a syringe, rather than to recommend them. Do not attempt to adjust your dose on your own—if you want to change your dose because of side effects or cost, always speak with your treatment team.
The “maximum dose” may not be the best dose for everyone
The numerical magnitude of weight loss matters—population-level thresholds have been demonstrated for improvement in some comorbidities (for example, certain metabolic diseases). However, each patient’s comorbidity profile, quality of life, drug tolerability, and ability to sustain treatment differ. According to the authors, fine-tuned titration, as with insulin, could be a valuable tool for finding the dose best suited to a person’s current profile throughout obesity treatment and adjusting it as needed.
Situations in which dose reduction (down-titration) may be reasonable
- Postoperative recovery: During periods when strong appetite suppression is undesirable, reducing the dose may help increase appetite—but in a controlled manner that also prevents rapid weight regain.
- Periods of financial constraints: In many parts of the world, patients pay for these drugs out of pocket. Dose reduction may ease the financial burden while preventing the rapid weight regain associated with abruptly stopping treatment altogether.
The authors emphasize that effective drugs delivered through unsuitable pens may deepen inequalities among patients with obesity.
Multidose pens are also used in Türkiye, but fine titration is not possible
- Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are available by prescription in Türkiye; the pens used are multidose pens (FlexTouch/KwikPen type), consistent with the “EU/Middle East” model described in the article, rather than the single-dose autoinjectors used in the United States.
- An honest limitation: During this research, we could not access an official, current source on the scope of SGK reimbursement for these drugs (particularly for the obesity/weight-management indication); for clear and current information, it is best to consult your pharmacist, physician, or SGK’s current Health Implementation Communiqué (SUT) list.
- For detailed, drug-specific information on approval, authorization, and reimbursement status in Türkiye, you can consult these articles on our website: What Is Semaglutide (Ozempic)?, What Is Wegovy?, What Is Tirzepatide (Mounjaro)?
What does it mean for patients?
There is promising but still early evidence that flexible/fine-tuned titration may reduce side effects and improve treatment continuation (a small pilot study, retrospective real-world data, and an ongoing study). If you experience side effects such as nausea or vomiting while using weight-loss injections or are considering adjusting your dose because of cost, the safest approach is to speak with your treatment team and jointly evaluate safe options (such as smaller approved dose increments, if available, or adjustment of dosing frequency), rather than doing it yourself through click-counting or withdrawing medication with a syringe. To learn what happens when these drugs are stopped, you can read our article The Main Overlooked Issue with Weight-Loss Injections: What Happens When You Stop? ; for side effects, you can read Side Effects of Weight-Loss Injections: When to Wait and When to See a Doctor .
An expert perspective: Personalized incretin titration
⚡ Why does this article matter?
Incretin-based drugs (semaglutide, tirzepatide) have transformed the treatment of obesity and type 2 diabetes, but current injection pens do not allow personalized dosing. This gap steers patients toward unsafe “homemade” dose-adjustment methods—although this is an expert opinion article, the safety problem it raises is concrete and current.✅ Strengths
The argument is supported by actual clinical data: a randomized pilot study (Eldor et al.) showed that flexible titration reduced side effects and discontinuation; real-world data (Pampanelli et al.) produced results in the same direction; and an ongoing randomized trial (NCT07574723) will allow the question to be tested in the obesity population as well.⚠️ Limitations
This is an expert opinion/letter, rather than a clinical trial. Its supporting studies are small, pilot-level, or retrospective; the efficacy of flexible titration in the population with obesity (without diabetes) has not yet been demonstrated in a randomized setting. Some authors have reported consulting/speaking relationships with companies producing the drugs discussed (such as Novo Nordisk and Eli Lilly)—this does not invalidate the argument but should be kept in mind when reading.🩺 What changes in practice?
For now, the practical change is a call to device manufacturers and regulators—the authors request the development of pens with continuous indicators that allow fine dose adjustment. The main message for patients is: if you want to adjust your dose because of side effects/cost, do so together with your physician through safe means.❓ Open questions
Will flexible titration provide similar benefits in people with obesity (without diabetes)? We await the results of NCT07574723. When will device manufacturers bring fine-adjustment pens to market? What is the effect of down-titration (dose reduction) strategies on long-term weight control?Cited studies: Eldor R et al., Diabetes Care 2025;48:1607-1611 (doi:10.2337/dc25-0690) · Rodriguez PJ et al., JAMA Netw Open 2025;8:e2457349 · Pampanelli S et al., Diabetes Obes Metab 2026;28:3623-3631 (doi:10.1111/dom.70538) · Trial registration: ClinicalTrials.gov NCT07574723.
Related topics: What Is Semaglutide (Ozempic)? · What Is Tirzepatide (Mounjaro)? · What Happens When You Stop Weight-Loss Injections? · Side Effects of Weight-Loss Injections
Was this article helpful?
Your feedback helps us improve our content.
